A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Inclusion Criteria:

• Written informed consent

• Aged 18 or above

• Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLCnot amenable to curative surgery or radiation. Part C and Part D: Stage IV squamousor non-squamous NSCLC not amenable to curative surgery or radiation. Part E: StageIV squamous NSCLC not amenable to curative surgery or radiation.

• Documented PD-L1 expression by PD-L1 IHC per local report.

• Part A and Part B: Confirmed progression during treatment with a CPI-includingregimen.

• Part C and Part D: No prior I/O treatment for metastatic NSCLC.

• Part E: No prior treatment for metastatic NSCLC.

• ECOG performance status of 0 or 1 at enrolment.

• Life expectancy of ≥ 12 weeks at enrolment.

• Have at least 1 measurable lesion per RECIST v1.1.

• Adequate bone marrow, liver and kidney function

Exclusion Criteria:

• Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphomakinase (ALK) fusion

• Documented test result for any other known genomic alteration for which a targetedtherapy is approved in first line per local standard of care (e.g. ROS1, NTRKfusions, BRAF, V600E mutation)

• Previous treatment with an anti-TIGIT therapy

• Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonaltherapy for cancer treatment.

• Part A and Part B: Primary or secondary resistance after treatment with 2 or moreregiments including a CPI.

• Part C and Part D: Any prior systemic treatment with an immune oncology agent (prioradministration of immune-oncology agent for curative intent to treat other invasivemalignancy is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

• Part E: Any prior systemic treatment for metastatic NSCLC, including but not limitedto chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.

• Symptomatic central nervous system (CNS) metastasis.

• Thromboembolic event within 3 months prior to enrolment.

• Other invasive malignancy within 2 years prior to screening.